Petros Pharmaceuticals Inc (PTPI)

$0.35

+0.01

(+1.51%)▲

Market is closed - opens 7 PM, 04 Oct 2024

Performance

  • $0.34
    $0.36
    $0.35
    downward going graph

    2.46%

    Downside

    Day's Volatility :5.17%

    Upside

    2.78%

    downward going graph
  • $0.28
    $2.27
    $0.35
    downward going graph

    19.4%

    Downside

    52 Weeks Volatility :87.57%

    Upside

    84.58%

    downward going graph

Returns

PeriodPetros Pharmaceuticals IncIndex (Russel 2000)
3 Months
-15.82%
0.0%
6 Months
-61.61%
0.0%
1 Year
-79.0%
0.0%
3 Years
-98.09%
-21.1%

Highlights

Market Capitalization
3.4M
Book Value
$0.87
Earnings Per Share (EPS)
-6.25
Wall Street Target Price
1.0
Profit Margin
-171.24%
Operating Margin TTM
-160.46%
Return On Assets TTM
-30.61%
Return On Equity TTM
-63.77%
Revenue TTM
4.1M
Revenue Per Share TTM
0.99
Quarterly Revenue Growth YOY
-28.7%
Gross Profit TTM
6.2M
EBITDA
-10.1M
Diluted Eps TTM
-6.25
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.13
EPS Estimate Next Year
-1.09
EPS Estimate Current Quarter
-0.77
EPS Estimate Next Quarter
-0.79

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Petros Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 185.71%

Current $0.35
Target $1.00

Technicals Summary

Sell

Neutral

Buy

Petros Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Petros Pharmaceuticals Inc
Petros Pharmaceuticals Inc
6.06%
-61.61%
-79.0%
-98.09%
-99.11%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-7.9%
-16.26%
4.26%
14.31%
28.12%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
4.13%
28.4%
27.47%
42.78%
42.78%
Zoetis Inc.
Zoetis Inc.
6.43%
19.89%
14.71%
0.87%
57.21%
Viatris Inc.
Viatris Inc.
-2.35%
-3.41%
20.31%
-13.55%
-28.95%
Catalent, Inc.
Catalent, Inc.
-0.21%
6.86%
37.82%
-53.05%
26.35%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Petros Pharmaceuticals Inc
Petros Pharmaceuticals Inc
NA
NA
NA
-2.13
-0.64
-0.31
NA
0.87
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
34.6
34.6
0.26
4.57
0.16
0.12
NA
24.87
Haleon Plc Spon Ads
Haleon Plc Spon Ads
34.42
34.42
1.51
0.4
0.07
0.04
0.01
1.82
Zoetis Inc.
Zoetis Inc.
38.14
38.14
2.65
5.82
0.49
0.14
0.01
10.94
Viatris Inc.
Viatris Inc.
224.4
NA
0.07
2.68
-0.03
0.03
0.04
16.36
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.86
0.2
-0.25
0.0
NA
19.91
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Petros Pharmaceuticals Inc
Petros Pharmaceuticals Inc
Buy
$3.4M
-99.11%
NA
-171.24%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$11.6B
28.12%
34.6
16.0%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$48.6B
42.78%
34.42
9.66%
Zoetis Inc.
Zoetis Inc.
Buy
$88.3B
57.21%
38.14
26.29%
Viatris Inc.
Viatris Inc.
Hold
$13.6B
-28.95%
224.4
-4.24%
Catalent, Inc.
Catalent, Inc.
Hold
$10.9B
26.35%
211.02
-23.81%

Insights on Petros Pharmaceuticals Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, -364.25K → 1.42M (in $), with an average increase of 64.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -8.02M → -662.02K (in $), with an average increase of 1112.5% per quarter

  • Vs CTLT

    In the last 1 year, Catalent, Inc. has given 37.8% return, outperforming this stock by 116.8%

  • Vs NBIX

    In the last 3 years, Petros Pharmaceuticals Inc has experienced a drawdown of -98.2%, however Neurocrine Biosciences Inc. resisted the overall trend and outperformed by 44.1%

Institutional Holdings

  • Virtu Financial LLC

    0.73%

  • TWO SIGMA SECURITIES, LLC

    0.56%

  • Vanguard Group Inc

    0.33%

  • Geode Capital Management, LLC

    0.32%

  • BlackRock Inc

    0.17%

  • Tower Research Capital LLC

    0.03%

Company Information

at petros, we are bringing new approaches to the most challenging conditions in men's health. we seek to understand the various health phases throughout a man’s journey. we collaborate with researchers, scientists, medical thought leaders and payers to ensure our therapies aid in restoring men’s body function to vitality.

Organization
Petros Pharmaceuticals Inc
Employees
21
CEO
Mr. John David Shulman
Industry
Miscellaneous

Discover More

FAQs